Literature DB >> 10029264

SSPE following neonatal measles infection.

Y Sawaishi1, T Abe, T Yano, K Ishikawa, G Takada.   

Abstract

The authors report a case of subacute sclerosing panencephalitis in a child who had measles during the neonatal period. At 3 years, 6 months of age, over a period of a few weeks, the patient lost the ability to sit unaided as a result of progressive truncal ataxia, without apparent cognitive changes, simulating acute cerebellar ataxia. His symptoms improved in 1 month, and he was able to walk again with support, but mental alteration and periodic mild head nodding on awakening followed. His illness was diagnosed as subacute sclerosing panencephalitis on the basis of the elevated titers of measles antibodies in the cerebrospinal fluid. Measles infection before 1 year of age is a risk factor of subacute sclerosing panencephalitis, but reports about patients with neonatal measles infection are rare. Immaturity of the brain at the time of measles infection may not only be a risk factor but may also influence the clinical course of the disease.

Entities:  

Mesh:

Year:  1999        PMID: 10029264     DOI: 10.1016/s0887-8994(98)00100-3

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  3 in total

1.  Editorial commentary: Measles in pregnancy is not child's play.

Authors:  Philip Alfred Brunell
Journal:  Clin Infect Dis       Date:  2014-01-22       Impact factor: 9.079

2.  Nodding syndrome in Mundri county, South Sudan: environmental, nutritional and infectious factors.

Authors:  P S Spencer; K Vandemaele; M Richer; V S Palmer; S Chungong; M Anker; Y Ayana; M L Opoka; B N Klaucke; A Quarello; J K Tumwine
Journal:  Afr Health Sci       Date:  2013-06       Impact factor: 0.927

Review 3.  Subacute sclerosing panencephalitis: results of the Canadian Paediatric Surveillance Program and review of the literature.

Authors:  Craig Campbell; Simon Levin; Peter Humphreys; Wikke Walop; Renee Brannan
Journal:  BMC Pediatr       Date:  2005-12-15       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.